Biosimilars Could Cut Spending for Biologic Therapy in the U.S.
FRIDAY, Jan. 21, 2022 -- Biosimilar drugs could drive down prices for biologic drugs and generate savings of about $38.4 billion between 2021 and 2025, according to a study published online Jan. 3 in the American Journal of Managed Care.
Andrew...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news